Vimarsana
Biggest News Aggregation in the World

Page 9 - Nasdaq Edit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Edit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Edit Today - Breaking & Trending Today

UBS Group AG Purchases 318,113 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) - Vimarsana News

UBS Group AG Purchases 318,113 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)

UBS Group AG lifted its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) by 357.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 407,014 shares of the company’s stock after buying an additional 318,113 shares during the quarter. UBS Group AG’s holdings in Editas Medicine were worth $3,610,000 at the end […]

Dynatrace (NYSE:DT) Releases Q1 Earnings Guidance - Vimarsana News

Dynatrace (NYSE:DT) Releases Q1 Earnings Guidance

Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) was the recipient of a large decline in short interest during the month of April. As of April 30th, there was short interest totalling 18,860,000 shares, a decline of 5.5% from the April 15th total of 19,950,000 shares. Based on an average trading volume of 1,770,000 shares, the […]

Editas Medicine (NASDAQ:EDIT) Raised to "Hold" at StockNews.com - Vimarsana News

Editas Medicine (NASDAQ:EDIT) Raised to "Hold" at StockNews.com

StockNews.com upgraded shares of Editas Medicine (NASDAQ:EDIT – Get Rating) from a sell rating to a hold rating in a research report sent to investors on Friday morning. EDIT has been the topic of several other research reports. Morgan Stanley decreased their price target on shares of Editas Medicine from $8.00 to $7.00 and set […]

Editas Medicine Announces Appointment of Erick J. Lucera as - Vimarsana News

Editas Medicine Announces Appointment of Erick J. Lucera as

Michelle Robertson to remain with Company until August 16, 2023...

Editas Medicine (NASDAQ:EDIT) Upgraded by StockNews.com to Hold - Vimarsana News

Editas Medicine (NASDAQ:EDIT) Upgraded by StockNews.com to Hold

Editas Medicine (NASDAQ:EDIT – Get Rating) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Friday. A number of other brokerages also recently issued reports on EDIT. SVB Leerink lifted their price target on Editas Medicine from $6.00 to $7.00 and gave the stock a […]

Source: wkrb13.com